Summary of Apellis Pharmaceuticals Conference Call Company Overview - **Company**: Apellis Pharmaceuticals (APLS) - **Event**: Bank of America Healthcare Conference - **Date**: May 13, 2025 - **Speakers**: Cedric Francois (CEO), Tim Sullivan (CFO) Key Points Industry Context - Discussion on the impact of recent executive orders related to drug pricing, particularly the "most favored nation" clause, which may affect Medicare pricing for Apellis' products [4][5][6] - Monitoring of tariff situations and their potential impact on gross margins [9] Product Insights - **Cyfoviry**: - Patients are responsible for approximately 20% copay, around $400 per injection [11][12] - A significant drop in funding from charitable foundations has affected patient access, leading to increased sample usage by physicians [14][15][19] - Despite challenges, there was a 4% quarter-over-quarter growth in patient treatments from Q4 to Q1 [19] - The company is only treating about 10% of the geographic atrophy patient population, indicating substantial unmet demand [20] Competitive Landscape - Apellis has gained market share against competitors, with a shift from 40% to 55% in new patients treated for Cyfoviry compared to 45% for the competitor [32][33] - Differentiation in efficacy and dosing frequency (every other month) is cited as a key driver for market share gains [34] Financial Health - Apellis ended the quarter with $358 million in cash, sufficient to reach profitability without needing to raise additional capital [45] Upcoming Launches - **C3G Program**: - Launch expected in August, targeting a patient population of approximately 5,000 [46][47] - Promising data showing 70% of patients had no trace of disease after six months of treatment [49] - Administered subcutaneously twice a week, similar to PNH [50] Future Directions - Plans to leverage learnings from previous product launches to ensure a strong market entry for C3G [56] - Ongoing development of a siRNA program in geographic atrophy, aiming to synchronize treatments for improved patient outcomes [58][59] - Two phase three trials in nephrology are set to begin in the second half of the year [60] Marketing and Awareness - A direct-to-consumer (DTC) campaign featuring Henry Winkler has shown early success in driving patient awareness and engagement [66][71] Guidance and Market Outlook - The company is cautious about providing sales guidance until after the C3G launch, given the recent challenges faced with Cyfoviry [62] Miscellaneous - Apellis has received recognition for its advertising campaigns, indicating effective marketing strategies [67][71] This summary encapsulates the critical insights and developments discussed during the conference call, highlighting Apellis Pharmaceuticals' strategic positioning, product performance, and future growth potential in the biotech industry.

Apellis Pharmaceuticals (APLS) reported first-quarter 2025 loss of 74 cents per share, wider than the Zacks Consensus Estimate of a loss of 36 cents. The company had incurred a loss of 54 cents in the year-ago quarter.Total revenues in the first quarter amounted to $166.8 million and missed the Zacks Consensus Estimate of $192 million. In the year-ago quarter, the company had reported revenues of $172.3 million.The top line lost 3% year over year as sales of Syfovre (pegcetacoplan injection) were impacted b ...

Apellis Pharmaceuticals, Inc. (APLS) reported $166.8 million in revenue for the quarter ended March 2025, representing a year-over-year decline of 3.2%. EPS of -$0.74 for the same period compares to -$0.54 a year ago. The reported revenue represents a surprise of -13.33% over the Zacks Consensus Estimate of $192.44 million. With the consensus EPS estimate being -$0.36, the EPS surprise was -105.56%. View all Key Company Metrics for Apellis Pharmaceuticals here>>> Shares of Apellis Pharmaceuticals have retur ...

Apellis Pharmaceuticals (APLS) Q1 2025 Earnings Call May 07, 2025 08:30 AM ET Company Participants Tracy Vineis - VP - CommunicationsCedric Francois - Co-Founder, President, CEO & DirectorTimothy Sullivan - CFODavid Acheson - EVP & Head - Global CommercialJonathan Miller - Managing DirectorCaroline Baumal - Chief Medical OfficerShrunatra Mishra - AssociateSteve Seedhouse - Biotechnology Equity ResearchAlexander Kelly - Biotech Equity Research AssociateAnnabel Samimy - Managing DirectorYigal Nochomovitz - Di ...

Apellis Pharmaceuticals (APLS) Q1 2025 Earnings Call May 07, 2025 08:30 AM ET Speaker0 Hello everyone and welcome to the Q1 twenty twenty five Appellis Pharmaceuticals Inc. Earnings Conference Call. At this time, all participants are in a listen only mode. After the presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. Now it's my pleasure to turn the call over to the Vice President of Communications, Tracy Veniz. The floor is yours. Speaker1 ...

Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.54 per share a year ago. These figures are adjusted for non-recurring items. What's Next for Apellis Pharmaceuticals? While Apellis Pharmaceuticals has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 27-1537290 (State or other ju ...

WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its first quarter 2025 financial results and business highlights. "In the first quarter, we were pleased to see continued growth in SYFOVRE injection demand—a key indicator of long-term market strength—and an increase in share of new patient starts, already reaching 55% in April. However, revenue was impacted by funding shortages at third-party co-pay assistance programs and a larger- than-expected ...

WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its first quarter 2025 financial results on Wednesday, May 7, 2025, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “Investors and Media” section of the company ...

The supplemental application submission supported by Phase 3 VALIANT results at Week 26: The U.S. Food and Drug Administration (FDA) on Tuesday accepted and granted Priority Review designation to Apellis Pharmaceuticals, Inc.'s APLS supplemental New Drug Application (sNDA) for Empaveli (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). C3G and primary IC-MPGN are rare kidney diseases. Excessive C3c deposits are a key marker of disease a ...